Table of Content

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary
3.1. Snippet by Phase
3.2. Snippet by Design
3.3. Snippet by Indication
3.4. Snippet by Service
3.5. Snippet by Region

4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing R&D Spending.
4.1.1.2. Favorable Regulatory Guidelines.
4.1.2. Restraints
4.1.2.1. High Cost and Low Success Probability.
4.1.3. Opportunity
4.1.4. Government Initiatives
4.1.5. Impact Analysis

5. Industry Analysis
5.1. Porter’s Five Forces Analysis
5.2. PEST Analysis
5.3. Regulatory Analysis
5.4. Pricing Analysis

6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Before COVID-19 Scenario
6.1.2. Present COVID-19 Scenario
6.1.3. Post COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers’ Strategic Initiatives
6.6. Conclusion

7. Russia-Ukraine War Analysis

8. Global Recession Analysis

9. Artificial Intelligence Impact Analysis

10. By Phase
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Phase
10.1.2. Market Attractiveness Index, By Phase
10.2. Phase III
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Phase II
10.4. Phase I
10.5. Phase IV

11. By Design
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Design
11.1.2. Market Attractiveness Index, By Design
11.2. Treatment Studies*
11.2.1. Introduction
11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
11.2.3. Randomized Control Trial
11.2.3.1. Double-Blind Randomized Trial
11.2.3.2. Single Blind Randomized Trial
11.2.3.3. Non-Blind Randomized Trial
11.2.4. Adaptive Clinical Trial
11.2.5. Non-Randomized Control Trial
11.3. Observational Studies
11.3.1. Prospective Cohort
11.3.1.1. Retrospective Cohort
11.3.1.2. Time Series Cohort
11.3.2. Case-Control Study
11.3.3. Cohort Study
11.3.4. Cross-Sectional Study
11.3.5. Ecological Study

12. By Indication
12.1. Introduction
12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
12.1.2. Market Attractiveness Index, By Indication
12.2. Oncology
12.2.1. Introduction
12.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
12.3. Immunological Diseases
12.4. Diabetes
12.5. Infectious diseases
12.6. Others

13. By Services
13.1. Introduction
13.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Services
13.1.2. Market Attractiveness Index, By Services
13.2. Laboratory Services
13.2.1. Introduction
13.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
13.3. Medical Device Testing Services
13.4. Clinical Trial Data Management Services
13.5. Bioanalytical Testing Services
13.6. Others

14. By Region
14.1. Introduction
14.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
14.1.2. Market Attractiveness Index, By Region
14.2. North America
14.2.1. Introduction
14.2.2. Key Region-Specific Dynamics
14.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Phase
14.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Design
14.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
14.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Services
14.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
14.2.7.1. The U.S.
14.2.7.2. Canada
14.2.7.3. Mexico
14.3. Europe
14.3.1. Introduction
14.3.2. Key Region-Specific Dynamics
14.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Phase
14.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Design
14.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
14.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Services
14.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
14.3.7.1. Germany
14.3.7.2. The U.K.
14.3.7.3. France
14.3.7.4. Italy
14.3.7.5. Spain
14.3.7.6. Rest of Europe
14.4. South America
14.4.1. Introduction
14.4.2. Key Region-Specific Dynamics
14.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Phase
14.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Design
14.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
14.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Services
14.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
14.4.7.1. Brazil
14.4.7.2. Argentina
14.4.7.3. Rest of South America
14.5. Asia-Pacific
14.5.1. Introduction
14.5.2. Key Region-Specific Dynamics
14.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Phase
14.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Design
14.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
14.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Services
14.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
14.5.7.1. China
14.5.7.2. India
14.5.7.3. Japan
14.5.7.4. Australia
14.5.7.5. Rest of Asia-Pacific
14.6. Middle East and Africa
14.6.1. Introduction
14.6.2. Key Region-Specific Dynamics
14.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Phase
14.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Design
14.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
14.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Services

15. Competitive Landscape
15.1. Competitive Scenario
15.2. Market Share Analysis
15.3. Mergers and Acquisitions Analysis

16. Company Profiles
16.1. Iqvia Holdings Inc. (Q2 Solutions)
16.1.1. Company Overview
16.1.2. Product Portfolio and Description
16.1.3. Financial Overview
16.1.4. Key Developments
16.2. Parexel International Corporation
16.3. Charles River Laboratories International, Inc.
16.4. Syneos Health, Inc.
16.5. WuXi AppTec Co., Ltd. (WuXi Clinical)
16.6. ICON plc
16.7. Thermo Fisher Scientific (Pharmaceutical Product Development LLC)
16.8. Azelix
16.9. Pharmaron Beijing Co., Ltd.
16.10. Celerion(*LIST NOT EXHAUSTIVE)

17. Appendix
17.1. About Us and Services
17.2. Contact Us